These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 26523025)

  • 21. Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry.
    Valero M; Sánchez-Piedra C; Freire M; Colazo M; Busquets N; Meriño-Ibarra E; Rodríguez-Lozano C; Manrique S; Campos C; Sánchez-Alonso F; Castrejón I
    Arthritis Res Ther; 2023 May; 25(1):86. PubMed ID: 37217997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and therapeutic management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: RADAR study.
    Gomez-Centeno A; Rubio-Romero E; Ovalles JG; Manrique-Arija S; Marsal-Barril S; Amarelo-Ramos J; Del Pino-Montes J; Muñoz-Fernández S; Bustabad S; Barbazán-Álvarez C
    Rheumatol Int; 2019 Dec; 39(12):2015-2024. PubMed ID: 31396685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of early treatment on physical function in daily management of rheumatoid arthritis: a 5-year longitudinal study of rheumatoid arthritis patients in the National Database of Rheumatic Diseases in Japan.
    Hirata A; Suenaga Y; Miyamura T; Matsui T; Tohma S; Suematsu E; Ohnaka K; Takayanagi R
    Int J Rheum Dis; 2018 Apr; 21(4):828-835. PubMed ID: 27126059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discontinuation of biologic DMARDs in a real-world population of patients with rheumatoid arthritis in remission: outcome and risk factors.
    Arnold S; Jaeger VK; Scherer A; Ciurea A; Walker UA; Kyburz D
    Rheumatology (Oxford); 2021 Dec; 61(1):131-138. PubMed ID: 33848332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Doppler ultrasound predicts successful discontinuation of biological DMARDs in rheumatoid arthritis patients in clinical remission.
    Terslev L; Brahe CH; Hetland ML; Georgiadis S; Ellegaard K; Juul L; Huynh T; Døhn UM; Fana V; Møller T; Krabbe S; Ørnbjerg LM; Glinatsi D; Røgind H; Hansen A; Nørregaard J; Jacobsen S; Jensen DV; Manilo N; Asmussen K; Boesen M; Rastiemadabadi Z; Morsel-Carlsen L; Møller JM; Krogh NS; Østergaard M
    Rheumatology (Oxford); 2021 Dec; 60(12):5549-5559. PubMed ID: 33748831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of biologics in Australian patients with rheumatoid arthritis: a large observational study: REAL.
    Nicholls D; Barrett R; Button P; Truman M; Bird P; Roberts L; Tymms K; Littlejohn G; Griffiths H
    Intern Med J; 2018 Oct; 48(10):1185-1192. PubMed ID: 29968400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis in real-world settings.
    Ochiai M; Tanaka E; Sato E; Inoue E; Abe M; Saka K; Sugano E; Sugitani N; Higuchi Y; Yamaguchi R; Sugimoto N; Ikari K; Nakajima A; Yamanaka H; Harigai M
    Mod Rheumatol; 2021 Jul; 31(4):790-795. PubMed ID: 33538611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study.
    An Y; Liu T; He D; Wu L; Li J; Liu Y; Bi L; Zhou B; Lin C; He L; Liu X; Li X; Yang N; Zhang Z; Song H; Wei W; Liu J; Bi Y; Li Z
    Clin Rheumatol; 2017 Jan; 36(1):35-43. PubMed ID: 27709444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Higher doses of methotrexate associated with discontinuation of oral glucocorticoids after initiation of biological DMARDs: A retrospective observational study based on data from a Japanese multicenter registry study.
    Suzuki M; Kojima T; Takahashi N; Asai S; Terabe K; Kaneko A; Hirano Y; Hanabayashi M; Oguchi T; Takagi H; Kanayama Y; Yabe Y; Funahashi K; Fujibayashi T; Tsuboi S; Ito T; Yoshioka Y; Ishikawa H; Sobue Y; Nishiume T; Yokota Y; Ishiguro N
    Mod Rheumatol; 2021 Jul; 31(4):796-802. PubMed ID: 33492191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity-results from the ENCOURAGE study, a prospective, international, multicenter randomized study.
    Yamanaka H; Nagaoka S; Lee SK; Bae SC; Kasama T; Kobayashi H; Nishioka Y; Ueki Y; Seto Y; Nishinarita M; Tamura N; Kimura N; Saito K; Tomita T; Nawata Y; Suzuki S; Ishigatsubo Y; Munakata Y; Makino Y; Inoue E; Tanaka Y; Takeuchi T;
    Mod Rheumatol; 2016 Sep; 26(5):651-61. PubMed ID: 26698929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Kearsley-Fleet L; Davies R; De Cock D; Watson KD; Lunt M; Buch MH; Isaacs JD; Hyrich KL;
    Ann Rheum Dis; 2018 Oct; 77(10):1405-1412. PubMed ID: 29980575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry.
    Mease PJ; Stryker S; Liu M; Salim B; Rebello S; Gharaibeh M; Collier DH
    Arthritis Res Ther; 2021 Sep; 23(1):236. PubMed ID: 34496952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system.
    Rashid N; Lin AT; Aranda G; Lin KJ; Guerrero VN; Nadkarni A; Patel C
    J Med Econ; 2016 Jun; 19(6):568-75. PubMed ID: 26766553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose tapering and discontinuation of biological therapy in rheumatoid arthritis patients in routine care - 2-year outcomes and predictors.
    Brahe CH; Krabbe S; Østergaard M; Ørnbjerg L; Glinatsi D; Røgind H; Jensen HS; Hansen A; Nørregaard J; Jacobsen S; Terslev L; Huynh TK; Jensen DV; Manilo N; Asmussen K; Brown Frandsen P; Boesen M; Rastiemadabadi Z; Morsel Carlsen L; Møller JM; Krogh NS; Hetland ML
    Rheumatology (Oxford); 2019 Jan; 58(1):110-119. PubMed ID: 30169706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disease activity after the discontinuation of biological therapy in inflammatory rheumatic diseases.
    Kádár G; Balázs E; Soós B; Laduver A; Keszthelyi P; Szekanecz Z; Kovács L
    Clin Rheumatol; 2014 Mar; 33(3):329-33. PubMed ID: 24497172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ultrasonographic Efficacy of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy in Rheumatoid Arthritis From a Multicenter Rheumatoid Arthritis Ultrasound Prospective Cohort in Japan.
    Nishino A; Kawashiri SY; Koga T; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Ueki Y; Yoshitama T; Eiraku N; Matsuoka N; Okada A; Fujikawa K; Hamada H; Tsuru T; Nagano S; Arinobu Y; Hidaka T; Kawakami A
    Arthritis Care Res (Hoboken); 2018 Dec; 70(12):1719-1726. PubMed ID: 29481732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan.
    Tanaka E; Inoue E; Yamaguchi R; Shimizu Y; Kobayashi A; Sugimoto N; Hoshi D; Shidara K; Sato E; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
    Mod Rheumatol; 2017 Mar; 27(2):227-236. PubMed ID: 27472516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physician Preferences and Variations in Prescription of Biologic Drugs for Rheumatoid Arthritis: A Register-Based Study of 4,010 Patients in Sweden.
    Kalkan A; Husberg M; Hallert E; Roback K; Thyberg I; Skogh T; Carlsson P
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1679-85. PubMed ID: 26097219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
    Rannio T; Asikainen J; Hannonen P; Yli-Kerttula T; Ekman P; Pirilä L; Kuusalo L; Mali M; Puurtinen-Vilkki M; Kortelainen S; Paltta J; Taimen K; Kauppi M; Laiho K; Nyrhinen S; Mäkinen H; Isomäki P; Uotila T; Aaltonen K; Kautiainen H; Sokka T
    Scand J Rheumatol; 2017 Nov; 46(6):425-431. PubMed ID: 28367663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.